Becton Dickinson

BDX

Market cap $43.9B

Healthcare may be considered a defensive sector, but not all healthcare stocks make for strong defensive plays. For one, consider it best to focus on healthcare companies with deep economic moats.

Becton, Dickinson, and Company is a cheap dividend stock that may become even cheaper in a market crash. Given Intuitive Surgical's prospects in its core market, the stock would be a no-brainer in a downturn.

FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD.

BDX seeks CE Mark for its Liverty TIPS Stent Graft, a next-gen device aimed at improving portal hypertension treatment and expanding its European footprint.

New study findings published in the Journal of Clinical Medicine highlight the ease of use and comfort of BD PureWick® Female External Catheter can support a better night's rest FRANKLIN LAKES, N.J. , April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new clinical findings revealing that women managing nighttime urinary incontinence reported better sleep and greater overall comfort when using the BD PureWick® Urine Collection System.

BDX launches HemoSphere Stream, enabling continuous non-invasive BP monitoring and boosting its advanced patient monitoring portfolio.

CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty™ TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union.

We bought four “new” holdings in the quarter. Two of the four — Blackstone and Otis — we have owned before. In IT, we exited Oracle and trimmed Broadcom. Our five-year investment in Oracle proved highly profitable as the company transitioned its business model from licensing to software-as-a-service. On the semiconductor side, we modestly reduced our position in Broadcom to fund our new investment in Taiwan Semiconductor.

New HemoSphere Stream™ Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients. FRANKLIN LAKES, N.J.